R udolf Maag is a Swiss billionaire entrepreneur who built his fortune in the medical devices industry. After earning an MBA from INSEAD, he began his career at Sandoz AG before joining the dental implant company Straumann. In a career-defining move in 1990, he acquired Straumann's medical device division, which he later spun off and listed as Stratec Medical. He successfully merged Stratec with Synthes, a global leader in orthopedic devices, in 1999.
Maag became a major shareholder in the combined entity, Synthes-Stratec, eventually holding a 15% stake. When Johnson & Johnson acquired Synthes for nearly $20 billion in 2012, Maag cashed out, solidifying his billionaire status. Since then, he has focused on investing his wealth in various sectors, including pharmaceuticals, construction, and hospitality (owning the Bellevue Hotel). He is also a notable philanthropist, supporting arts and cultural institutions in Switzerland.
Advertisement
Rudolf Maag is a Swiss businessman whose fortune stems from his ventures in medical devices.
Maag earned an M.B.A. from Insead in 1973 and began his career at pharmaceutical company Sandoz AG of Switzerland. He later moved to dental giant Straumann, where, in 1990, he bought out the medical device division and took it public as Stratec Medical.
Rudolf Maag's career is marked by his strategic restructuring and consolidation within the European medical device industry. After founding Stratec Medical from a leveraged buyout in 1990, he later engineered a major deal in 1999 by merging Stratec with Swiss medical device powerhouse Synthes.
Through this deal, Maag built up a significant 15% stake in Synthes, which was later sold to Johnson & Johnson, securing his billionaire status from the successful acquisition and exit.
Advertisement
Got an M.B.A. from Insead.
Bought out the medical device division of Straumann and took it public as Stratec Medical.
Merged Stratec with Synthes.
Synthes was later sold to Johnson & Johnson.
Rudolf Maag's wealth is concentrated in the proceeds from the sale of his stake in the consolidated medical device entity.
Advertisement
Advertisement
No publicly available quotes.
Advertisement
+2.22% | +$31.75M
+0.28% | +$8.41M
This profile is compiled from verified biographical and financial records:
All information is cross-referenced with public sources for accuracy; some narrative sections are AI-assisted summaries.
If you find any inaccuracies, please report them to admin@redcarpetlife.in
Sponsored Content